| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Summary.: I.C.I. 46,474, the trans-isomer of 1-(p-β-dimethylaminoeth-oxyphenyl-1,2-diphenylbut-1-ene, is very effective in terminating early pregnancy by preventing implantation when given during the first 4 days after insemination to female rats. In this species, the compound is weakly and atypically oestrogenic and is also anti-oestrogenic, as indicated by its inhibitory effect on the response to exogenous oestrogens of the vaginal epithelium (cornification) and uterus (weight-increase). It is suggested that it can prevent implantation in rats by virtue of its anti-oestrogenic activity, i.e. by counteracting the oestrogen-release from the ovaries which is believed to occur on the 4th day and upon which implantation appears to depend.
The corresponding cis-isomer (I.C.I. 47,699) is very different in its properties and behaves in all respects like a conventional oestrogen (orally active—e.g. dienoestrol). In rats it is very much more potent as an oestrogen than I.C.I. 46,474—by which its uterotrophic action is inhibited. On the other hand the trans-isomer is the more potent of the two in inducing vaginal cornification in ovariectomized mice.
This article has been cited by other articles:
 |
|
 |
|
  V. C. Jordan The 38th David A. Karnofsky Lecture: The Paradoxical Actions of Estrogen in Breast Cancer--Survival or Death? J. Clin. Oncol., June 20, 2008; 26(18): 3073 - 3082. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. C. Jordan The Rise of Raloxifene and the Fall of Invasive Breast Cancer J Natl Cancer Inst, June 18, 2008; 100(12): 831 - 833. [Full Text] [PDF]
|
|
|
|
|
|
V. C. Jordan and B. W. O'Malley Selective Estrogen-Receptor Modulators and Antihormonal Resistance in Breast Cancer J. Clin. Oncol., December 20, 2007; 25(36): 5815 - 5824. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. C. Jordan Tamoxifen or Raloxifene for Breast Cancer Chemoprevention: A Tale of Two Choices Point Cancer Epidemiol. Biomarkers Prev., November 1, 2007; 16(11): 2207 - 2209. [Full Text] [PDF]
|
|
|
|
|
|
V. C. Jordan SERMs: Meeting the Promise of Multifunctional Medicines J Natl Cancer Inst, March 7, 2007; 99(5): 350 - 356. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Sonmezer and K. Oktay Fertility preservation in young women undergoing breast cancer therapy. Oncologist, May 1, 2006; 11(5): 422 - 434. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K-M Rau, H-Y Kang, T-L Cha, S A Miller, and M-C Hung The mechanisms and managements of hormone-therapy resistance in breast and prostate cancers Endocr. Relat. Cancer, September 1, 2005; 12(3): 511 - 532. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. C. Jordan Medroxyprogesterone Acetate and Metastases: Of Mice and (wo)Men J Natl Cancer Inst, May 4, 2005; 97(9): 619 - 621. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Sonmezer and K. Oktay Fertility preservation in female patients Hum. Reprod. Update, May 1, 2004; 10(3): 251 - 266. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L. Smith and B. W. O'Malley Coregulator Function: A Key to Understanding Tissue Specificity of Selective Receptor Modulators Endocr. Rev., February 1, 2004; 25(1): 45 - 71. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. C. Jordan Targeting antihormone resistance in breast cancer: a simple solution Ann. Onc., July 1, 2003; 14(7): 969 - 970. [Full Text] [PDF]
|
|
|
|
 |
|
 E. V. Jensen and V. C. Jordan The Estrogen Receptor: A Model for Molecular Medicine Clin. Cancer Res., June 1, 2003; 9(6): 1980 - 1989. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. C. Jordan Is Tamoxifen the Rosetta Stone for Breast Cancer? J Natl Cancer Inst, March 5, 2003; 95(5): 338 - 340. [Full Text] [PDF]
|
|
|
|
 |
|
 D. P. McDonnell, C. E. Connor, A. Wijayaratne, C.-y. Chang, and J. D. Norris Definition of the Molecular and Cellular Mechanisms Underlying the Tissue-selective Agonist/Antagonist Activities of Selective Estrogen Receptor Modulators Recent Prog. Horm. Res., January 1, 2002; 57(1): 295 - 316. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. C. Jordan, S. Gapstur, and M. Morrow Selective Estrogen Receptor Modulation and Reduction in Risk of Breast Cancer, Osteoporosis, and Coronary Heart Disease J Natl Cancer Inst, October 3, 2001; 93(19): 1449 - 1457. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. C. Jordan Selective Estrogen Receptor Modulation: A Personal Perspective Cancer Res., August 1, 2001; 61(15): 5683 - 5687. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Clarke, F. Leonessa, J. N. Welch, and T. C. Skaar Cellular and Molecular Pharmacology of Antiestrogen Action and Resistance Pharmacol. Rev., March 1, 2001; 53(1): 25 - 72. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. P. Nephew, E. Osborne, R. A. Lubet, C. J. Grubbs, and S. A. Khan Effects of Oral Administration of Tamoxifen, Toremifene, Dehydroepiandrosterone, and Vorozole on Uterine Histomorphology in the Rat Experimental Biology and Medicine, March 1, 2000; 223(3): 288 - 294. [Abstract] [Full Text]
|
|
|
|
|
|
V. C. Jordan How Is Tamoxifen's Action Subverted? J Natl Cancer Inst, January 19, 2000; 92(2): 92 - 94. [Full Text] [PDF]
|
|
|
|
|
|
J. I. MacGregor Schafer, H. Liu, D. A. Tonetti, and V. C. Jordan The Interaction of Raloxifene and the Active Metabolite of the Antiestrogen EM-800 (SC 5705) with the Human Estrogen Receptor Cancer Res., September 1, 1999; 59(17): 4308 - 4313. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. C. Jordan and M. Morrow Tamoxifen, Raloxifene, and the Prevention of Breast Cancer Endocr. Rev., June 1, 1999; 20(3): 253 - 278. [Abstract] [Full Text]
|
|
|
|
 |
|
 Y. Lavrovsky, R. K. Tyagi, S. Chen, C. S. Song, B. Chatterjee, and A. K. Roy Ribozyme-Mediated Cleavage of the Estrogen Receptor Messenger RNA and Inhibition of Receptor Function in Target Cells Mol. Endocrinol., June 1, 1999; 13(6): 925 - 934. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. J. Mann, R. A. Keri, and J. H. Nilson Transgenic Mice with Chronically Elevated Luteinizing Hormone Are Infertile Due to Anovulation, Defects in Uterine Receptivity, and Midgestation Pregnancy Failure Endocrinology, June 1, 1999; 140(6): 2592 - 2601. [Abstract] [Full Text]
|
|
|
|
|
|
J. I. Macgregor and V. C. Jordan Basic Guide to the Mechanisms of Antiestrogen Action Pharmacol. Rev., June 1, 1998; 50(2): 151 - 196. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Shughrue, M. V. Lane, and I. Merchenthaler Regulation of Progesterone Receptor Messenger Ribonucleic Acid in the Rat Medial Preoptic Nucleus by Estrogenic and Antiestrogenic Compounds: An in Situ Hybridization Study Endocrinology, December 1, 1997; 138(12): 5476 - 5484. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
